Robert P. Badavas, a member of the board at Hercules Capital, Inc. (NASDAQ:HTGC), bought 3,658 shares of the company's common stock on March 26, 2026, a Form 4 filed with the Securities and Exchange Commission shows. The acquisitions were executed at an average price of $14.35 per share, with individual trades ranging from $14.31 to $14.39, producing a total transaction value of $52,492.
The filing specifies that the shares were obtained through Badavas' election to receive stock instead of cash as director compensation. After the transaction, Badavas is recorded as directly holding 5,070 shares of Hercules Capital common stock. He also continues to have indirect ownership of 122,073 shares through the Robert P. Badavas Trust of 2007, according to the filing.
The purchase arrives as HTGC stock trades near its 52-week low of $13.70 and has fallen about 20% over the last six months. The company currently offers a dividend yield of 13.24%. Per InvestingPro Tips, Hercules Capital has maintained dividend payments for 22 consecutive years.
Separately, Hercules Capital released preliminary results for the fourth quarter of 2025, estimating net asset value per share in a range between $12.10 and $12.16. That estimate represents a modest increase from the previous quarter's NAV per share of $12.05.
On the financing front, Hercules amended its loan agreement with Savara Inc. to provide for up to an additional $75 million in funding, contingent on U.S. Food and Drug Administration approval of Savara's drug MOLBREEVI. That amendment is part of Savara's broader plan to support a drug launch with a total of $150 million in non-dilutive capital.
Market analysts and short sellers have recently flagged risks tied to Hercules' portfolio makeup. Piper Sandler downgraded Hercules Capital's rating from Overweight to Neutral, citing the firm's concentrated exposure to the software sector and potential disruption risks related to artificial intelligence. The investment bank also lowered its price target to $17.50 from $20.50.
In addition, a short-report published by Hunterbrook questioned the sustainability of Hercules Capital's dividend and challenged the valuation of its software-related debt, which constitutes about 35% of the company's loan portfolio. Hunterbrook disclosed it holds a short position in Hercules Capital.
The transaction, the preliminary NAV figures, the Savara loan amendment, the Piper Sandler downgrade, and the Hunterbrook short report together sketch a complex backdrop for Hercules Capital as insiders, counterparties, analysts, and short sellers adjust their positions and assessments. The director's election to take stock compensation increases his direct holding modestly while keeping his substantial indirect stake intact through his trust.
Given the mix of insider buying by a director, a small sequential NAV uptick, and external concerns tied to sector concentration and dividend durability, investors and observers will likely continue to monitor Hercules Capital's quarterly results and portfolio composition for signs of stabilization or further stress.